Company attributes
Other attributes
VistaGen Therapeutics is a publicly owned, clinical-stage biopharmaceutical company based in San Francisco, California that was founded in 1998 by Ralph Snodgrass. The company is focused on developing treatments for depression and other central nervous system (CNS) disorders including, major depressive disorder, neuropathic pain, social anxiety disorder, and suicidal ideation.
VistaGen's product pipeline consists of three items, AV-101, PH10, and PH94B. AV-101 is an oral NMDAR GlyB (N-methyl-D-aspartate receptor glycine B) antagonist, which is a type of glutamate receptor modulators having the potential to treat MDD. Phase 2 clinical trials designed to evaluate the efficacy and safety of it's adjunctive use is ongoing. The US FDA has granted Fast Track designation for AV-101 as both a potential adjunctive treatment of MDD and as a non-opiod treatment for neuropathic pain. The company has also received Notices of Allowances from IP Australia and the Japan Patent Office (JPO) .
PH94B is an intranasal treatment for the rapid onset, on demand treatment of social anxiety disorder (SAD) symptoms. The treatment is developed from VistaGen's proprietary compounds called pherines. Another treatment being developed from pherines, is PH10, which activates nasal chemosensory receptors that in turn engage GABA (gamm-aminubutyic acid) and CRH (corticotropin-releasing hormones) neurons in the hypothalamus, amygdala, prefrontal cortex, and hippocampus. As another potential treatment for MDD, VistaGen is preparing to advance PG10's development in Phase 2b clinical trials.
